Despite facing many difficulties, JMI is moving forward with pride and high potentials at home and abroad. 

The JMI Group is one of the world renowned and diversified global conglomerates of 32 companies with more than 7,000 highly dedicated and educated workforces particularly in the healthcare services.

Recently JMI Syringes and Medical Devices Ltd (JSMDL) has received a purchase order to export made in Bangladesh Auto Disable (AD) syringes to Dubai for the Covid vaccination programme.

A total of 45 million AD syringes will be exported from July to September this year, the company said in a statement.

The United Nations Children’s Fund (UNICEF) has confirmed the purchase order of the syringes to be exported Dubai. Besides, UNICEF also requested the JSMDL for supplying syringes until June 2023. Earlier the JSMDL had exported AD syringes to United States, Indonesia, Pakistan, and Nepal.

AD syringe is a specialised product used for vaccination. The Covid vaccination across the world has been going on using this special type syringe. Only a few numbers of companies in the world have the facilities to produce AD syringes, while the Bangladeshi JSMDL is one of them. The company has had the PQS certification from the World Health Organization since 2012.

Nipro Asia Pte Ltd, exclusively owned by Nipro Corporation, Japan, and JMI Marketing Ltd, one of the companies of JMI Group in Bangladesh, have formed a joint venture called Nipro JMI Marketing Ltd. This has been deemed an exceptionally promising milestone in the medical devices market in Bangladesh.

Despite the Covid-19 situation, Japanese Conglomerate Nipro Corporation has invested around Tk128 crore ($15 million) as foreign direct investment (FDI) by merging with JMI Group to launch Nipro JMI Marketing Ltd. With this investment Nipro Corporation's total investment in JMI Group stands at around Tk680 crore ($80 million), read a press release.

Nipro JMI Marketing Ltd will market the medicine and medical equipment manufactured by JMI Group on the local market in Bangladesh. Moreover, the company will source essential medical equipment across the globe and market the products at home and abroad after ensuring their quality.

According to Shigetomi Hisao, the representative of NIPRO JMI Group has achieved our trust by producing quality products. That is why we have not hesitated to further invest with the company. We hope that the Nipro JMI Marketing Ltd like our other ventures with the JMI Group will satisfy the consumers by ensuring the products' quality.

JMI Group Managing Director Md Abdur Razzaq said the new FDI from Japanese Nipro Corporation proves the quality of JMI Group as well as the products they manufacture.

"We firmly believe that the new partnership will make our commitment to the healthcare sector in Bangladesh even stronger; ensuring our capability of providing quality customer service, smoother distribution and efficient sales and marketing process," he added.

JMI Group is a leading manufacturer and supplier of medical devices and pharmaceuticals in the country. It has been producing essential medical devices through joint venture programmes since 1999.

According to another report, Nipro Corporation, listed on the first section of the Tokyo Stock Exchange, Japan, is one of the biggest manufacturers of medical devices, pharmaceuticals and pharma-packaging in the world. JMI Group and Nipro Group have collaboratively worked on the development of the healthcare sector in Bangladesh with its joint ventures: Nipro JMI Company Ltd, Nipro JMI Pharma Ltd, Nipro JMI Dialysis Centre, and JMI Syringes and Medical Devices Ltd. Nipro JMI Marketing Ltd is the fifth joint venture established in the partnership between JMI Group and Nipro Group.

It is learnt that government will procure three crore of syringes for Covid-19 vaccine from JMI Syringes & Medical Devices Ltd. 

JMI is to provide the syringes in five installments according to the agreement. In the first phase, it has been asked to provide 66 lakh syringes by 31 January. 

The remaining amount will be procured in four phases by 20 June. 

According to sources, the government will spend Tk 17,82,00,000 at the price of Tk 5.40 each.

JMI Syringes & Medical Devices Ltd, a public limited company established in April 1999 in Bangladesh with joint collaboration of Republic of Korea, supplied 1 crore syringes and medical device across the country to make the government’s target to inoculate highest number of people in a day marking 75th anniversary of Prime Minister Sheikh Hasina.

The company, which has earned a much reputation in the global arena by producing adequate number of Auto Disable (AD) syringes amid Covid-19 vaccination programme, came up with the supply on September 28. 

Earlier, on September 26, Directorate General of Health Services (DGHS) sent a letter to JMI authorities asking for the required number of syringes and medical device.

JMI officials said to have supplied the syringe and other equipment to all parts of the country before start of vaccination on birthday of Prime Minister Sheikh Hasina.

JMI has also housed Japanese investment with good record of exporting AD syringe and other medical equipment to various countries including the USA.

JMI Syringes and Medical Devices Ltd has decided to invest over Tk5 crore to increase its auto disable (AD) syringe production capacity by one-third, as the demand for the special product increased home and abroad.